Champions Oncology to Host Webinar on Patient-Derived Xenograft Program for Clinical Advancement
Hackensack, NJ – February 11, 2016 – Champions Oncology (CSBR) announced today that it will host a live, complimentary webinar titled, “Patient Derived Xenograft Program for Clinical Advancement”, on Monday, February 29, from 1:30 AM to 2:30 PM Eastern Time. The webinar will feature Neal Goodwin, PhD, Vice President of Corporate Research Development at Champions Oncology.
Conducted in conjunction with Cambridge Healthtech Institute, the webinar will provide information on how the Champions TumorGraft platform is being used for conducting high through-put translational medicine trials across a multitude of patient tumor models, including acute myelogenous leukemia (AML). Additionally, there will discussion of how co-clinical and matched PDX-directed trials are being implemented through several industry and academic partnerships.
This informative webinar will specifically cover :
- Introduction to the PDX algorithm
- Overview of Champions Oncology PDX tumor bank
- Overview of Champions Oncology co-clinical program
- AML modeling
- CD34+ HSC-derived humanized PDX models for immuno-therapy testing
Interested participants can register for the webinar here.
About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Champions TumorGraft® technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or Champions TumorGraft PDX models, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. PDX tumor models in the Champions TumorGraft platform are procured through agreements with a number of institutions in the U.S. and overseas as well as through Champions’ Personalized Oncology Solutions busines